98%
921
2 minutes
20
Objective: This study aimed to compare the efficacy of dexamethasone alone and dexamethasone-ondansetron combined for preventing postoperative nausea and vomiting (PONV) in patients undergoing orthognathic surgery.
Methods: Patients scheduled to undergo mandibular orthognathic surgery who were 18 to 50 years of age and American Society of Anesthesiologists physical status I or II were enrolled. Dexamethasone 6.6 mg was administered after intubation, followed by either ondansetron 4 mg (group DO) or saline placebo (group D) 15 minutes before the end of surgery. Nausea severity was assessed at 3 times postoperatively (immediately after the end of anesthesia, 2 hours later, and 24 hours later) using a 11-point numeric rating scale (NRS). If a patient complained of postoperative nausea or vomited, the NRS score was reevaluated. If the NRS score was 3 or higher, intravenous metoclopramide 10 mg was administered for PONV rescue. Assessed data included nausea NRS scores, vomiting, metoclopramide use, and other patient demographics.
Results: Mean nausea NRS scores at 2 hours were significantly lower in group DO vs group D (0.3 vs 2.1; P = .003), but differences in vomiting rates were not significant (P > .05). PONV rescue rates with metoclopramide were lower overall and at 2 hours later in group DO (P < .001).
Conclusion: Dexamethasone combined with ondansetron was more effective in preventing early postoperative nausea and reducing need for PONV rescue than dexamethasone alone for patients undergoing orthognathic surgery.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11922510 | PMC |
http://dx.doi.org/10.2344/23-0019 | DOI Listing |
Int J Surg
September 2025
Experimental Tumorpathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Drug Des Devel Ther
September 2025
Department of Anesthesiology, Peking University People's Hospital, Beijing, People's Republic of China.
Background: The dopamine D2/D3 antagonist amisulpride has demonstrated its superiority and efficacy in prophylaxis of postoperative nausea and vomiting (PONV). Given the branded intravenous amisulpride (Barhemsys) has not been approved in China, there is unmet clinical need for amisulpride. Our primary objective was to ascertain the efficacy and safety of the generic intravenous amisulpride (QLG2069) in the prophylaxis of PONV.
View Article and Find Full Text PDFSurg Endosc
September 2025
Metabolic and Obesity Surgery Unit, ARNAS G. Brotzu, Cagliari, Italy.
Reg Anesth Pain Med
September 2025
Department of Anesthesiology, Critical Care & Pain Management, Hospital for Special Surgery, New York, New York, USA
Reg Anesth Pain Med
September 2025
Department of Anesthesiology and Reanimation, Ministry of Health Ankara Bilkent City Hospital, Ankara, Turkey.